A trial to learn how safe elecoglipron is and how well it works in adults living with obesity or excess body weight with or without type 2 diabetes

Brief summary (registry, in English)

To determine whether elecoglipron is superior to placebo for percent body weight loss in two independent studies, in adults with obesity or overweight with or without T2DM

What you commit to

• Study type: Interventional · Phase 3
• Planned participants: 1010
• 64 sites in 4 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with obesity or overweight. Some may have type 2 diabetes, others not. It tests elecoglipron against placebo for weight loss.

Age

18 years or older

Sex

Women and men can join.

Disease stage

Study 1: BMI 30 kg/m2 or higher, or BMI from 27 to under 30 kg/m2 with at least one weight-related condition (high blood pressure, prediabetes, abnormal blood fats, heart and blood vessel disease, or sleep apnea). Study 2: BMI 27 kg/m2 or higher with type 2 diabetes.

Earlier treatment

At least one self-reported unsuccessful diet attempt to lose weight. Body weight stable for 90 days before screening (within 5% change).

Biomarker or test result

Study 2: type 2 diabetes diagnosis, or no diagnosis but HbA1c 6.5% (48 mmol/mol) or higher at screening.

Main reasons for not taking part

• Study 1: diagnosis of type 1 or type 2 diabetes
• Study 2: type 1 diabetes, or HbA1c 10% (86 mmol/mol) or higher
• Study 2: current or expected treatment for diabetic eye disease, or more than one severe low blood sugar episode in the past 180 days
• Past acute pancreatitis (unless from resolved gallstones and gallbladder removal) or chronic pancreatitis
• Medullary thyroid cancer or multiple endocrine neoplasia type 2 in the person or in close family

Read by machine on 9 Nov 2026.

Who cannot take part

Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on EU CTIS (euclinicaltrials.eu)

Sites (64)

Sites in registry order. Save your city in your profile to sort them by distance.

Are you the coordinator? Confirm the details